A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Conditions: Pancreatic Adenocarcinoma; Hepatocellular Carcinoma; Squamous Cell Carcinoma; Mesothelioma; Non-squamous Non-small-cell Lung Cancer; Triple Negative Breast Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Gastric Adenocarcinoma Interventions: Drug: TAK-500; Drug: Pembrolizumab Sponsor: Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Mesothelioma | Research | Study